US medical company Tempus, valued at over $3 billion, have also partnered with LINK to launch their AI genomic tests in the UK. Nice indication for Rhythm investors that LINK is a 'go-to' organisation.
Tempus appear to be powering along in the US, they recently gained pre-approval for an FDA application. They also have a collaboration with Pfizer, plus an office in South Africa, interesting!
Check out the news updates on their website.
RHY Price at posting:
42.5¢ Sentiment: Buy Disclosure: Held
